



INDO-BANGLA PHARMACEUTICALS LIMITED

729, COLLEGE ROAD, BARISAL SADAR, BARISAL-8200, BANGLADESH

PHONE: +88-0967-8777995; FAX: +88-04-312174977

E-mail: info@indo-banglapharma.com;

WEBSITE: www.indo-banglapharma.com

Statement of Financial Position As at 30 September 2018 (Provisional & Un-audited)

Particulars	Amounts in Taka	
	30th Sep, 2018	30th June, 2018
ASSETS:		
Non-current Assets:	685,877,456	654,019,821
Property, Plant and Equipment	680,331,536	648,473,901
Capital Work In Progress	5,545,920	5,545,920
Current Assets:	1,059,039,068	565,947,615
Inventories	162,810,575	166,752,790
Trade & Other Receivables	196,420,917	188,296,158
Advance, Deposits and Prepayments	123,383,172	119,219,048
Cash and Cash equivalents	576,424,404	91,679,619
TOTAL ASSETS	1,744,916,524	1,219,967,436
OWNER'S EQUITY AND LIABILITIES		
Owner's Equity:	1,265,290,361	1,036,100,643
Share Capital	930,000,000	730,000,000
Retained Earnings	335,290,361	306,100,643
NON-CURRENT LIABILITIES	73,159,797	67,249,601
Deferred Tax Liability	73,159,797	67,249,601
Current Liabilities:	406,466,366	116,617,192
Provision for WPPF	9,635,018	7,576,461
Trade Payables	5,589,887	6,541,572
IPO Refund Liability	282,978,040	-
Provision for Taxes	103,645,036	97,573,822
Liabilities for Expenses	4,618,385	4,925,336
TOTAL OWNER'S EQUITY AND LIABILITIES	1,744,916,524	1,219,967,436
Net Asset Value (NAV) Per Share	13.20	14.19

Statement of Profit or Loss and Other Comprehensive Income For the 1st Quarter ended 30 September 2018

Provisional & Un-audited

Particulars	Amounts in Taka	
	30th Sep, 2018	30th Sep, 2017
Net Sales Revenue	165,882,809	159,230,850
Less: Cost of Sales	98,801,141	94,933,835
Gross Profit	67,081,668	64,297,016
Less: Operating Expenses:	25,802,618	24,208,839
Administrative Expenses	6,937,649	6,143,640
Selling & Distributing Expenses	18,864,969	18,065,199
Profit from Operations	41,279,049	40,088,176
Add: Non Operating Income:	1,950,635	1,975,802
Profit before Contribution to WPPF & Welfare Fund	43,229,684	42,063,978
Less: Contribution to WPPF & Welfare Fund	2,058,556	2,003,047
Profit before Tax	41,171,128	40,060,932
Less: Income Tax Expenses:	11,981,409	14,021,326
Current Tax	6,071,214	7,737,202
Deferred Tax	5,910,196	6,284,124
Net Profit for the period	29,189,718	26,039,606
Basic Earnings per share (EPS)	0.38	0.36
Diluted Earnings per share (EPS)	0.31	0.36

Statement of Changes in Equity For the 1st Quarter ended 30 September 2018

Particulars	Share Capital	Retained Earnings	Provisional & Un-audited
			Total Equity
Balance as at 01-07-2018	730,000,000	306,100,643	1,036,100,643
Issue of share Capital (IPO)	200,000,000	-	200,000,000
Net Profit for the period	-	29,189,718	29,189,718
Balance as at 30-09-2018	930,000,000	335,290,361	1,265,290,361

Particulars	Share Capital	Retained Earnings	Provisional & Un-audited
			Total Equity
Balance as at 01-07-2017	730,000,000	207,606,643	937,606,643
Net Profit for the period	-	26,039,606	26,039,606
Balance as at 30-09-2017	730,000,000	233,646,249	963,646,249

Statement of Cash Flows For the 1st Quarter ended 30 September 2018

Provisional & Un-audited

Particulars	Amounts in Taka	
	30th Sep, 2018	30th Sep, 2017
Cash Flow from Operating Activities		
Cash receipts from customers	157,758,050	158,675,560
Cash receipts from others income	1,950,635	2,019,912
Cash payment to Suppliers	(92,934,890)	(119,308,126)
Cash payment to Employees	(19,780,777)	(18,167,115)
Cash payment to Others	(11,337,940)	(10,122,535)
Cash Generate from operation	35,655,079	13,097,696
Cash payment against income Tax	(2,564,793)	(2,988,143)
Net Cash from Operating Activities	33,090,286	10,109,554
Cash Flow from Investing Activities		
Acquisition of property, plant and equipment	(325,140)	(423,300)
Paid for Work In Progress	-	(1,245,850)
Advance paid for L/C Margin Machinery	(24,150,400)	-
Net Cash used in Investing Activities	(24,475,540)	(1,669,150)
Cash Flow from Financing Activities		
Proceeds from issue of share capital	200,000,000	-
Cash payment to IPO Expenses	(6,848,001)	-
Receive excess of IPO Application	282,978,040	-
Net Cash from Financing Activities	476,130,039	-
Net increase in Cash and Cash equivalents	484,744,785	8,440,404
Cash and Cash Equivalents at beginning of the period	91,679,619	116,812,231
Cash and Cash Equivalent at end of the Period	576,424,404	125,252,635
Net Operating Cash Flows Per Share (NOCFPS)	0.43	0.14
Sd/- Chief Financial Officer		Sd/- Director
Sd/- Company Secretary		Sd/- Managing Director & CEO
Place: Dhaka Date: November 14, 2018		

*The details of the Published First Quarterly Financial Statements are available in the website of the company. The address of the website is www.indo-banglapharma.com